Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.

Aims: To explore the biomarker for predicting the occurrence of adverse events in myeloma patients treated by intravenous bortezomib, we measured proteasome activity in peripheral blood mononuclear cells.

Methods: Samples were obtained from 34 bortezomib-naïve patients. Proteasome activity was measured at pre- and postchemotherapy phase by using a synthetic substrate.

HIV-associated peripheral T-cell lymphoma with a cytotoxic phenotype.

Most human immunodeficiency virus (HIV)-related lymphomas are of B-cell origin, and the T-cell type is very rare. We experienced a Japanese case of HIV-associated peripheral T-cell lymphoma (HIV-PTCL). Sudden intestinal hemorrhage necessitated emergent surgical resection of the small intestine, in which an ulcerative lesion was detected.

[Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma].

A 74-year-old man, who had mantle cell lymphoma treated with several anticancer drugs including rituximab, was admitted to our hospital because of gait disturbance and progressive paralysis of the right lower limb. T2-weighted MR image showed multiple high intensity lesions in the left parietal lobe. Suspected of being cerebral invasion of lymphoma, high-dose methotrexate was begun, but the patient died of sepsis without neurological improvement.